Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks